ADVANCED BIOMEDICAL TECHNOLOGIES, INC. Forward Looking Statements
This section of the report includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like: believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. Actual results could differ materially from those anticipated in these forward looking statements as a result of any number of factors, including those set forth in this Quarterly Report, and in the Company's most recent Annual Report on Form 10-K filed onMarch 20, 2020 . All written and oral forward-looking statements made in connection with this Quarterly Report on Form 10-Q that are attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. Given the uncertainties that surround such statements, you are cautioned not to place undue reliance on such forward-looking statements, which apply only as of the date of this quarterly report. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or our predictions. Overview
The following discussion is an overview of the important factors that management focuses on in evaluating our businesses, financial condition and operating performance and should be read in conjunction with the financial statements included in this Quarterly Report on Form 10-Q.
The Company is subject to a number of risks similar to other companies in the medical device industry. These risks include but are not limited to rapid technological change, uncertainty of market acceptance of our products, uncertainty of regulatory approval, competition from substitute products and larger companies, the need to obtain additional financing, compliance with government regulation, protection of proprietary technology, product liability, and the dependence on key individuals. Our Business
We are engaged in the business of designing, developing, manufacturing and marketing of biomaterial internal fixation devices. We hold one medical device permit from theNational Medical Products Administration of the PRC ("NMPA") for our product - polymer orthopaedic internal fixation screws and two patents issued by theState Intellectual Property Office of the P.R.C . ("SIPO"). Our polyamide materials, their uses and manufacturing processes are protected by Patent No. ZL971190739. A new patent, No. ZL201410647464.1 titled "Bone Fracture Plate Made of High Polymer Materials" was granted to us inJanuary 2018 . Our polyamide materials are used in producing screws, binding wires, rods and related products. These products are used in a variety of applications including orthopaedic trauma, sports related medical treatment, or cartilage injuries, and reconstructive dental procedures. At this time, our company is the sole patent holder and market permit holder of PA technologies inChina , as well as the only company currently engaged in clinical trials, manufacturing and marketing for PA orthopaedic internal fixation devices in the PRC. Our products are made of a very unique material called PA6-P(MMA-CO-NVP)-HA ("PA"). Our PA products, such as screws, binding wires, rods, suture anchors and rib-pins consist of enhanced fibers and high molecular polymers which are designed to facilitate quick healing of complex fractures in many areas of the human skeletal system. 4
Our products offer a number of significant advantages over existing metal implants and the first generation of degradable implants (i.e. PLLA) for patients, surgeons and other customers including:
1. A notably reduced need for a secondary surgery to remove implant due to
post-operative complications, therefore avoiding unnecessary risk and expense
on all patient care;
2. Enhancing the performance of the materials by manufacturing them to be easily
fitted to each patient, forming an exact fit;
3. Improving the biological activity of materials. Clinical trial results have
shown that PA implants promote a progressive shift of load to the new bone
creating micro-motion and thereby avoiding bone atrophy due to 'stress
shielding';
4. Reducing the chance of post-operative infection;
5. Stimulate bone tissues to facilitate effective biological integration,
benefitting the regeneration of bone;
6. Ease of post-operative care i.e. no distortion during x-ray imaging;
7. Simple and cost-effective to manufacture.
Our products are designed to replace the traditional internal fixation device
made of stainless steel and titanium and overcome the limitations of previous
generations of products such as PLA and PLLA. Our laboratory statistics show
that our PA products have a higher mechanical strength, last longer in
degradation ratio and are more evenly absorbed form outer layer inwards as
compared with similar materials such as PLA and PLLA. Thus PA allows increased
restoration time for bone healing and re-growth. The Company's polymer
orthopaedic internal fixation screws received approval from the National Medical
Products Administration of the PRC ("NMPA") in April 2018 . We launched our sales
campaign at the end of our fiscal year ended October 31, 2019 and achieved a
milestone in the Company's history by generating revenue through the salesof our PA Screws.
NMPA Application Process and Approval for Polymer Screws
The Company first submitted its application for PA Screws to the NMPA (formerly the SFDA/CFDA) in 2008. The application has been withheld by the NMPA pending additional clinical trial cases. This is due to the amended NMPA regulations, which unlike previous regulations require the applicant to specify the position on the body where the clinical trial is carried out. Our amended NMPA application has specified the ankle fracture as the body part of our clinical trial. This is because bones around this part carry most of the body weight. Due to the uniqueness of our material, there were no established NMPA Product Standards that we could follow during our application process for our PA Screws. To establish our own Product Standards, the Company had been carrying out extra tests. The Company submitted its Product Standards and supplementary reports to the NMPA in 2014. InDecember 2016 , the Company received a notice from the NMPA requesting supplementary report as part of the review process. The Company completed the supplementary report and submitted it to the NMPA inJune 2017 .
In
Process of Human Trials As ofJanuary 31, 2020 , for medical study and comparison purpose, the Company has completed a total of 83 successful clinical human trial cases, including 71 cases on ankle fractures and 57 successful PA Binding Wire trial cases. We have been conducting human trials at the 6 state level hospitals recognized by NMPA for clinical trials in different cities throughoutChina ; includingNanchang ,Changsha ,Luoyang ,Nanning andTianjin . The cities and provinces where our clinical trial hospitals are based will be the initial target regions on our marketing plan. These regions are both densely populated and have experienced high or above medium economic growth. The clinical trials for the Company's PA Screws have been completed with 100 percent success rate. Having gained NMPA approval for PA Screws, the Company is planning to start clinical trials on series of orthopaedic products the Company has developed using the same unique biomaterial. 5 Government Regulation
Medical implant devices/products manufactured or marketed by the Company inChina are subject to extensive regulations by the NMPA. Pursuant to the related laws and acts, as amended, and the regulations promulgated there under (the "NMPA Regulations"), the NMPA regulates the clinical testing, manufacture, labeling, distribution and promotion of medical devices. The NMPA also has the authority to request repair, replacement, or refund of the cost of any device manufactured or distributed by the Company. Under the NMPA Regulations, medical devices are classified into three classes (class I, II or III), the basis of the controls deemed necessary by the NMPA to reasonably assure their safety and efficacy. Under the NMPA's regulations, class I devices are subject to general controls (for example, labeling and adherence to Good Manufacturing Practices ("GMP") requirements) and class II devices are subject to general and special controls. Generally, class III devices are those which must receive premarket approval by the NMPA to ensure their safety and efficacy (for example, life-sustaining, life-supporting and certain implantable devices, or new devices which have not been found substantially equivalent to legally marketed class I or class II devices). The Company is classified as a manufacturer of class III medical devices. Current NMPA enforcement policy prohibits the marketing of approved medical devices for unapproved uses. Before a new device can be introduced into the market inChina , the manufacturer generally must obtain NMPA marketing clearance through clinical trials. Since the Company is classified as a manufacturer of Class III medical devices, the Company must carry out all clinical trials in pre-selected NMPA approved hospitals. Manufacturers of medical devices for marketing inChina are required to adhere to GMP requirements. Enforcement of GMP requirements has increased significantly in the last several years and the NMPA has publicly stated that compliance will be more strictly scrutinized. From time to time the NMPA has made changes to the GMP and other requirements that increase the cost of compliance. Changes in existing laws or requirements or adoption of new laws or requirements could have a material adverse effect on the Company's business, financial condition and results of operations. There can be no assurance that the Company will not incur significant costs to comply with applicable laws and requirements in the future or that applicable laws and requirements will not have a material adverse effect upon the Company's business, financial condition and results of operations. Regulations regarding the development, manufacturing and sale of the Company's products are subject to change. The Company cannot predict the impact, if any, that such changes might have on its business, financial condition and results of operations. Results of Operations
The "Results of Operations" discussed in this section merely reflect the
information and results of the Company for the period from
6 Revenues
The Company achieved a milestone in its history by generating sales revenue at the end of the fiscal year endedOctober 31, 2019 . As ofJanuary 31, 2020 , the Company's net sales increased from$11,657 to$60,501 compared with previous quarter. Due to the COVID-19 pandemic, non-essential operations have been cancelled in hospitals nationwide inChina . We expect the sales of our PA Screws to fall in the second quarter of 2020, and gradually recover during the third quarter as the COVID-19 cases ease off inChina . Our management team is continuously looking for fundraising possibilities for sales and marketing expansion, product improvement, machinery upgrades, facility expansions and continuous research and development. Our facility is located inShenzhen, China , which is built to meet the GMP standards. Our facility covers about 865 square meters, which includes the combined facilities of offices, laboratories, and workshops. There is one production line for the PA Screw and another production line for the PA Binding Wire. The annual production capabilities of each production line are 100,000 pieces for PA Screw, and 240,000 packs for the PA Binding Wires. Both production lines, at their maximum production capacities are capable of generating approximately$30,000,000 in annual revenue.
Estimate current production lines in full capacity
Total Turnover
Output Quantity (Max.) Price at ex-factory ($) ($)
PA Screw 100,000 (piece) 180 18,000,000
PA Binding Wire 240,000 (pack) 50 12,000,000
Total: 30,000,000
China's Marketing Analysis:
We have established long term relationships with many hospitals and national
distributors in China . Ms. Hui Wang , the Company's CEO, has over 25 years' sales
experience in medical distribution. Professor Shangli Liu, our chief medical
advisor, is one of the highest ranked orthopedic doctors in China as well as
being highly renowned in the rest of the world. He will assist the Company in
nationwide product promotion and joint projects with associated academic
institutions and medical schools. During product development and clinical trial
stages, we developed close relationships with many major national hospitals. We
expect these relationships to boost our revenue generation.
- Patients
- Advanced technology level
- Performance and price of the materials
China has gradually entered theOld Age Society . It is expected that there will be 245 million people over 60 years of age by 2020, and, according to the survey of 50 years old, the incidence of osteoporosis is as high as 60%, accompanied by osteoporosis, fracture, bone necrosis, disability and other diseases, resulting in continued high demand of orthopaedic implant medical devices. (Source: The UN;Shenwan Hongyuan Securities research report). 7
The Company has advantages and more opportunities over others competitors due to:
- No other similar patent registrations in
- We are the only company to receive market approval and permission to perform PA clinical trials by the NMPA to the best of our knowledge.
- We have a timing advantage over other Chinese companies; other companies would need to successfully complete preclinical testing for the NMPA in order to obtain clinical trial permits.
- Under new regulations by the NMPA, it will take at least 5-10 years for clinical trials of new materials.
- Our patented material enables us to rapidly diversify our product line according to market trend and demand.
Number of Hospitals at the end of
Statistic and Census report by the National Health Commission of the People's Republic of China
(February 2020)
February 2020 February 2019 Increase / (Decrease)
Total No. of Hospitals 34,104 33,125 979
Public Hospital 11,915 11,960 (45 )
Private Hospital 22,189 21,165 1,024
Hospital Rating
AAA 2,762 2,582 180
AA 9,730 9,061 669
A 11,153 10,850 303
Unrated 10,459 10,632 (173 )
In general, technological advancements and the marketing potential within Asia
are the biggest factors in driving significant growth within the global
orthopedic devices market. Another major factor that positively influences this
market is the growing number of aging baby boomers with active lifestyles. This
sector represents a large portion of the total population.
Research and Development
Research and development costs related to both present and future products are expensed as incurred. Total expenditure on research and development charged to general and administrative expenses for the quarter endedJanuary 31, 2020
and 2019 was$56,780 and$16,979 . We expect research and development expenses to grow as we continue to invest in basic research, clinical trials, product development and in our intellectual property. The Company will be working closely with medical institutions and research universities to expedite future clinical trials of upcoming series of polymer fixation devices, including Intramedullary Nailing Fixation, Binding Wires, Micromodule Screws & Plates, Maxillofacial & Craniofacial Plates, and Rib Pins. Marketing Strategy The Company has been conductingPre-Market Research before its PA Screws application was approved by the NMPA inApril 2018 . The research is intended to estimate the potential market success of the company's products that can be expected. The research also beyond the Company's initial market -China , and covers international markets. Based on the results of ourPre-Market Research and the positive feedbacks we have received from trade shows and industrial conferences, it is the Company's intention to apply for additional international regulatory approvals in due course. 8
The Company will market its products through a hybrid sales force comprised of a
managed network of independent regional distributors/sales agents (80%) and
direct sales representatives (20%) in
There are two ways the Company will generate revenue, 1) through our nationwide and regional distributors and 2) through our direct sales channels.
The Company is currently working to have its products registered on multiple provincial Group Purchasing Organization (GPO) platforms. A few distributors have made deposit payment. The Company is working with distributors to develop sales channels and have its products reaching hospitals. Impact of COVID-19 Outbreak
The Company's primary business is carried out through its subsidiary,
The Company has identified the following areas that have been adversely affected by COVID-19 pandemic:
1. Operation: Our facilities in
lockdown, travel restrictions and quarantine requirements. This affected our
accounting and marketing departments mostly because a large number of staff
couldn't come back to office as they were not allowed to travel or have
14-day quarantine before they come back to work. As the crisis is easing off
in
2. Manufacturing: We have sufficient raw material stock for 2 months and our
production should not be affected. However, if COVID-19 pandemic persists and
continues beyond
short of raw material supply.
3. Marketing: We launched our sales campaign in
increased in the quarter ended
plans have been disrupted by COVID-19 pandemic because almost all the
hospitals in China have been dealing with COVID-19 and non-essential
operations have been postponed or cancelled.
The Company has been working with its business partners and workforce through crisis planning, effective communication and co-operation to minimize the negative impact of the COVID-19 pandemic.
Finance Costs
As ofJanuary 31, 2020 andOctober 31, 2019 , a stockholder and four related parties had loaned a total of$5,044,984 and$4,916,638 respectively to the Company as unsecured loans repayable on demand and interest is charged at 7% per annum on the amount due. Total interest expenses on advances from a stockholder and the related parties accrued for the three months endedJanuary 31, 2020 and 2019 were$80,254 and$75,507 respectively. As ofJanuary 31, 2020 andOctober 31, 2019 , the Company owed$298,911 and$280,514 respectively to the directors for advances made on an unsecured basis, repayable on demand. Total imputed interest expenses on advances from directors, calculated at 5% per annum, recorded as additional paid-in capital amounted to$3,389 and$3,148 for the three months endedJanuary 31, 2020 and 2019 respectively. 9 Net Loss
The net loss attributable to common stockholders for the three months endedJanuary 31, 2020 and 2019 were$63,789 and$252,523 respectively. We started to generate revenue at the end of our fiscal year from inception toOctober 31, 2019 before our sales campaign was disrupted by the COVID-19 pandemic, but we have to incur operating expenses for the upkeep of the Company and the clinical trials.
Liquidity and Capital Resources
We had a working capital deficit of$6,780,031 and$6,577,273 as ofJanuary 31, 2020 andOctober 31, 2019 respectively. Our working capital deficit is due to the fact that we received the NMPA approval for one product inApril 2018 and we are in the process to produce, market and sell our product inChina . We only started our sales campaign and our sales revenues were not able to cover our expenses and we relied on loans from our related parties and stockholders.
Cash Flows
Net cash used in operating activities was$51,860 and$199,767 in the three months endedJanuary 31, 2020 and 2019 respectively. This amount was attributable primarily to the net loss after adjustment for non-cash items, such as depreciation, loss on disposal of property and equipment, imputed interest on advances from directors, and others like charges in other receivables and prepaid expenses and other payables and accrued expenses.
We recorded net cash used of$525 and$25,043 in investing activities in the three months endedJanuary 31, 2020 and 2019 respectively. This amount reflected purchases of property and equipment, primarily for research and development
to our facilities.
Net Cash Provided by Financing Activities
Net cash provided by financing activities in the three months endedJanuary 31, 2020 and 2019 was$54,805 and$234,622 respectively, which represented advances from a stockholder, directors and related parties, loan repayment to directors and advances to a related company.
Operating Capital and Capital Expenditure Requirements
Our ability to continue as a going concern and support the commercialization of current products is dependent upon our ability to market our product while obtaining additional financing in the near term. We anticipate that such funding will be in the form of marketing of our products and equity financing from sales of our common stock. However, there is no assurance that we will be able to raise sufficient funding from the sale of our products and common stock to fund our business plan should we decide to proceed. We anticipate our sales revenue will not meet our financial needs in 2020 and we need to rely on advances from our related parties and stockholders in order to continue to fund our business operations. We believe that our existing cash, cash equivalents atJanuary 31, 2020 , will be insufficient to meet our cash needs. Our minimum cash requirement for the next 12 months is projected to be$100,000,000 . This amount may increase if we decide to start clinical trials on new products. The management is actively pursuing additional funding and strategic partners, which will enable the Company to implement our business plan, business strategy, to continue research and development, clinical trials or further development that may arise. 10 We intend to spend more to support the commercialization of current products and on research and development activities, including new products development, regulatory and compliance, clinical studies, and the enhancement and protection of our intellectual property portfolio.
OFF-BALANCE SHEET ARRANGEMENTS
We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our investors. CRITICAL ACCOUNTING POLICIES The preparation of our financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including but not limited to those related to income taxes and impairment of long-lived assets. We base our estimates on historical experience and on various other assumptions and factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Based on our ongoing review, we plan to adjust to our judgments and estimates where facts and circumstances dictate. Actual results could differ from our estimates. We believe the following critical accounting policies are important to the portrayal of our financial condition and results and require our management's most difficult, subjective or complex judgments, often because of the need to make estimates about the effect of matters that are inherently uncertain. 1. Property and equipment
Property and equipment are stated at cost, less accumulated depreciation. Expenditures for additions, major renewals and betterments are capitalized and expenditures for maintenance and repairs are charged to expense as incurred.
Depreciation is provided on a straight-line basis, less estimated residual value over the assets estimated useful lives. The estimated useful lives of the assets are 5 years. 2. Long-lived assets
In accordance with FASB Codification Topic 360 (ASC Topic 360), "Accounting for the impairment or disposal of Long-Lived Assets", long-lived assets and certain identifiable intangible assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. For purposes of evaluating the recoverability of long-lived assets, the recoverability test is performed using undiscounted net cash flows related to the long-lived assets. The Company reviews long-lived assets to determine that carrying values are not impaired. 3. Inventory
Inventory is stated at the lower of cost (using weighted average basis) and net realizable value.
11 4. Fair value of financial instruments FASB Codification Topic 825 (ASC Topic 825), "Disclosure About Fair Value of Financial Instruments," requires certain disclosures regarding the fair value of financial instruments. The carrying amounts of other receivables and prepaid expenses, other payables and accrued liabilities and due to a stockholder, directors and related parties approximate their fair values because of the short-term nature of the instruments. The management of the Company is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial statements. 5. Income taxes The Company accounts for income taxes underThe Financial Accounting Standards Board (FASB) Codification Topic 740-10-25 ("ASC 740-10-25"). Under ASC 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period included the enactment date. 6. Research and Development
Research and development costs related to both present and future products are expensed as incurred.
7. Foreign currency translation The reporting currency of the company's financial statements is the US dollar. The financial statements of the Company's subsidiary denominated in currencies other than the US dollar are translated into US dollars using the closing rate method. The balance sheet items are translated into US dollars using the exchange rates at the respective balance sheet dates. The capital and various reserves are translated at historical exchange rates prevailing at the time of the transactions while income and expenses items are translated at the average exchange rate for the year. All exchange differences are recorded within equity.
ADOPTION OF NEW ACCOUNTING STANDARD
Leases
The Company has initially adopted ASU No. 2016-02, Leases (Topic 842) as of1 November 2019 using the modified retrospective method. In addition, the Company elected the transition method permitted under the ASU 2018-11 issued inJuly 2018 , which allowed the Company to initially apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of accumulated deficits in the period of adoption. The cumulative effect of the changes made to the consolidated balance sheet as of1 November 2019 for the adoption of the new leases standard was as follows: Balances at Adjustments Balances at October 31, on adoption of November 1, 2019 ASU 2016-02 2019 ASSETS Right-of-use assets $ - $ 74,139$ 74,139 CURRENT LIABILITIES Lease liabilities, current portion - (43,732 ) (43,732 ) NON-CURRENT LIABILITIES Lease liabilities, net of current portion -
(33,333 ) (33,333 )
Cumulative-effect adjustment to opening balance of accumulated deficit $ - $ (2,926 )$ (2,926 )
In determining the lease liability and corresponding right-of-use asset for each lease, the Company calculated the present value of future lease payments using the Company's incremental borrowing rate. The incremental borrowing rate was determined with reference to the interest rate applicable to borrowings from related parties disclosed in Note 4, Related Parties Transactions. The reported results for the three months endedJanuary 31, 2020 reflect the adoption of ASC 842 guidance while the reported results for the three months endedJanuary 31, 2019 were prepared and continue to be reported under the
guidance of ASC 840, Leases. 12
© Edgar Online, source
